Using SDDSs to co-deliver ICD inducers and PD-1/PD-L1 antibodies not only activates anti-tumor immunity but also prevents immunosuppression, which is a promising technique for tumor immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.